The headline numbers (quick view)
2025 annual Part D out-of-pocket cap (MOOP): $2,000.
2026 annual Part D out-of-pocket cap (MOOP): $2,100. This is the 2025 cap adjusted for the program’s indexing rules for 2026.
Maximum Part D deductible allowed by law: up to $590 in 2025 and $615 in 2026 (plans may choose lower or no deductible).
What the MOOP (out-of-pocket cap) actually means
The MOOP (maximum out-of-pocket) is a calendar-year limit on what you pay for covered Part D drugs (deductibles, copayments, coinsurance for covered drugs) — once you reach that cap, for the rest of the year you generally won’t have to pay copays or coinsurance for covered Part D drugs. Premiums, drugs not covered by your plan, and some services are not counted toward this cap.
Why the 2026 number is still a win (even though it rose from $2,000 → $2,100)
It prevents catastrophic drug bills. Before the cap, beneficiaries could face very high, open-ended costs for specialty or high-priced drugs. A predictable annual cap protects people from catastrophic exposure and budgeting surprises. That structural protection remains in 2026.
The small increase reflects indexing — not a policy rollback. The bump to $2,100 for 2026 is an annual adjustment tied to drug-spending trends, not the removal of the cap. That keeps the protection sustainable while reflecting real cost changes.
More beneficiaries will feel the benefit thanks to broader design changes. The Part D redesign and Inflation Reduction Act changes aim to shift more cost pressure away from beneficiaries (negotiation of drug prices, benefit redesign). That means overall out-of-pocket exposure for many people is projected to fall compared with pre-reform levels.
Example scenarios
Someone with chronic prescriptions that previously could run into the thousands in the middle of the year now has a hard cap: once their covered drug spending reaches $2,100 in 2026, their covered prescriptions should be free (no further copays/coinsurance) for the rest of the year.
If your plan’s deductible is $615 in 2026 (the legal maximum), you pay that first—then copays/coinsurance—until the cumulative amounts you’ve paid for covered drugs hit the $2,100 MOOP. (Plans often use different cost-sharing approaches, so the path to the cap varies.)
Important details & caveats
Not every dollar you pay counts toward the cap. Monthly premiums, drugs your plan doesn’t cover, or amounts paid for non-covered products aren’t counted toward the MOOP. Always confirm with your plan what counts.
Plan formularies, tiering and prior authorization still matter. Even with a cap, you can face delays, substitutions, or step therapy rules that affect access and timing. Beneficiaries should monitor formulary changes during Annual Enrollment.
The deductible rose slightly (2025 → 2026). The statutory maximum deductible increased from $590 in 2025 to $615 in 2026 — plans may choose a lower deductible or none at all. That tradeoff (higher deductible vs. lower copays/premium) is something to watch when selecting a plan.
Practical tips for beneficiaries (what to do now)
Check your 2026 plan’s Summary of Benefits — verify the deductible, how cost-sharing applies, and what counts toward the MOOP.
Compare formularies and total expected annual cost (premiums + expected OOP) — the cap is powerful, but a lower premium plan with higher cost-sharing could still be more expensive for some. Use your drug list to compare.
Ask your plan/agent about manufacturer assistance and exceptions — some assistance programs don’t count toward MOOP, and switching options may be available.
If you take high-cost specialty meds, plan ahead — reach out to your prescriber and plan early in the year to avoid interruptions, and confirm whether prior authorization or step therapy applies.
Bottom line
The 2026 Part D MOOP (set at $2,100) keeps in place a meaningful protection introduced under recent reforms: a hard cap on what beneficiaries must pay for covered prescription drugs in a calendar year. The modest increase from $2,000 to $2,100 reflects standard indexing — it doesn’t weaken the protection — and the broader Part D redesign aims to reduce overall out-of-pocket exposure for many beneficiaries. For people who take multiple or high-cost medications, the cap is a clear financial safety net and therefore a real win.
